Antonio Llombart-Cussac, Aleix Prat, José Manuel Pérez-García, José Mateos, Tomás Pascual, Santiago Escrivà-de-Romani, Agostina Stradella, Manuel Ruiz-Borrego, Begoña Bermejo de Las Heras, Marleen Keyaerts, Patricia Galvan, Fara Brasó-Maristany, Juan José García-Mosquera, Thomas Guiot, María Gion, Miguel Sampayo-Cordero, Serena Di Cosimo, Jhudit Pérez-Escuredo, Manuel Atienza de Frutos, Javier Cortés, Geraldine Gebhart
BACKGROUND: The PHERGain study (NCT03161353) is assessing early metabolic responses to neoadjuvant treatment with trastuzumab-pertuzumab and chemotherapy de-escalation using a [18 Fluorine]fluorodeoxyglucose-positron emission tomography ([18 F]FDG-PET) and a pathological complete response-adapted strategy in HER2-positive (HER2+) early breast cancer (EBC). Herein, we present RESPONSE, a PHERGain substudy, where clinicopathological and molecular predictors of [18 F]FDG-PET disease detection were evaluated...
April 8, 2024: European Journal of Nuclear Medicine and Molecular Imaging